Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid

Pharmacotherapy

Volumn 34, Issue 9, 2014, Pages 891-900

  Flanagan, Shawn ^a   Fang, Edward ^a   Muñoz, Kelly A ^a   Minassian, Sonia L ^a   Prokocimer, Philippe G ^a  

^a Cubist ^*  (United States)

Author keywords

intravenous; pharmacokinetics; tedizolid phosphate

Indexed keywords

PLACEBO; TEDIZOLID; ANTIINFECTIVE AGENT; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE;

ABNORMAL DREAMING; ADULT; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFLUENZA; INJECTION SITE BLEEDING; INJECTION SITE COLDNESS; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PARESTHESIA; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; PILOT STUDY; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; VOMITING; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; ERYTHEMA; HEMATOMA; INFUSION RELATED REACTION; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; SKIN SWELLING; UNITED STATES; VOLUME OF DISTRIBUTION; BIOAVAILABILITY; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; ORGANOPHOSPHATES; OXAZOLES; PILOT PROJECTS; YOUNG ADULT;

EID: 84907977684     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1458     Document Type: Article

References (18)

1. McCaig LF, McDonald LC, Mandal S, Jernigan DB,. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006; 12: 1715-23.
2. Prokocimer P, De Anda C, Fang E, Mehra P, Das A,. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013; 309: 559-69.
3. U.S. Food and Drug Administration. Guidance for industry-acute bacterial skin and skin structure infections: developing drugs for treatment. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ ucm071185.pdf. Effective October 2013. Accessed November 13, 2013.
4. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE,. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis 2009; 49: 65-71.
5. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl 2): S114-32.
6. Dryden MS,. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65 (Suppl 3): iii35-44.
7. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011; 55: 583-92.
8. Urbina O, Ferrandez O, Espona M, Salas E, Ferrandez I, Grau S,. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Des Devel Ther 2013; 7: 243-65.
9. Schaadt R, Sweeney D, Shinabarger D, Zurenko G,. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009; 53: 3236-9.
10. Flanagan SD, Bien PA, Munoz KA, Minassian SL, Prokocimer PG,. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 2014; 24: 240-50.
11. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P,. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH 2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014 June 6 [Epub ahead of print].
12. Dunn K, O'Reilly A, Silke B, Rogers T, Bergin C,. Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study. Int J Clin Pharm 2011; 33: 208-14.
13. Tan JS, File TM Jr,. Management of community-acquired pneumonia: a focus on conversion from hospital to the ambulatory setting. Am J Respir Med 2003; 2: 385-94.
14. Athanassa Z, Makris G, Dimopoulos G, Falagas ME,. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 2008; 68: 2469-81.
15. Jackson A,. Infection control-a battle in vein: infusion phlebitis. Nurs Times 1998; 94 (68): 71.
16. Fang E, De Anda C, Das A, Prokocimer P,. Efficacy and safety results from the ESTABLISH-2 ABSSSI study comparing IV and oral tedizolid phosphate and linezolid. Paper presented at: European Society of Clinical Microbiology and Infectious Diseases; Berlin, Germany; April 27-30, 2013.
17. Huttunen KM, Raunio H, Rautio J,. Prodrugs-from serendipity to rational design. Pharmacol Rev 2011; 63: 750-71.
18. Heimbach T, Oh DM, Li LY, et al. Absorption rate limit considerations for oral phosphate prodrugs. Pharm Res 2003; 20: 848-56.